Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GARDASIL®9 immunogenicity in adult women vs young adult women
NCT03158220Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2017
- Primary completion
- Nov 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
Phase 3, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (2 arms), sponsored by Merck & Co. Primary endpoint: Anti-HPV Geometric Mean Titers for Each Anti-HPV Type. Started Sep 2017; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03158220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03158220.